It was today that Isodiol International Inc (OTCMKTS:ISOLF) applauded FDA’s decision on the much anticipated Epidiolex belonging to GW Pharmaceuticals (NASDAQ:GWPH). It is a product that will play a huge role in treating seizures linked to two forms of epilepsy.
The CEO of Isodiol International, Inc Marcos Agramont opined, “Fundamentally, the approval of Epidiolex will have no legal impact on the sale of hemp-derived CBD for consumer goods. The fact that the FDA has stated that they will focus on proliferation and illegal marketing of unapproved CBD-containing products with unproven medical claims is welcomed.”
It was in a recent interview that the company’s spokesperson outlined that the move by FDA added significant value to their finished pharmaceutical products (FPP).
Hemp-derived CBD products have lately started getting increased visibility and that follows the approval by FDA. The Hemp Farming Act was recently passed by the U.S. Congress, a decision that will see to it that hemp and hemp-derived products are permanently established as agricultural commodities in the United States.
The company has called upon its wide support base to take advantage of the U.S. Hemp Roundtable’s web portal in connecting with the various Congressmen. It is pushing an agenda of getting them to back up the passage of the Hemp Farming Act.
We have found a handful of Hemp Oil companies that qualify to be all organic and grown in the U.S.A. Here is one of the best all organic CBD oil products on the market. It’s by Greenleaf Farms, I believe you can get up to 30% by visiting them today!
Isodiol and its future plans
Isodiol is looking forward to expand its business operations as well as maximize shareholder value. It will be resorting to the consolidation of its issued and outstanding ordinary share capital (“Common Shares”).
The Consolidation is almost reaching completion and up listing to a major exchange in the United States is the major priority. It is about offering the company the access it needs to the US based institutional investors. After the up listing, the company will be in a position to capitalize on new opportunities as well as maximize growth.
Isodiol has also outlined a strategy for balanced, long-term growth in a bid to boost its shareholder value. Regulations are changing from time to time and the company is planning to leverage on the various changes related to hemp and CBD around the globe.